Physician profile
Scott E Morris
NPI 1871910083
$5,595.69
in general payments reported to CMS, 2019-2025
36 companies · $929 in 2025
The $929 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $869 · 2021: $982 · 2022: $446 · 2023: $934 · 2024: $764 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $991.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.46 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $611.28 | 2021-2025 | |
| Novo Nordisk INC | $596.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $476.06 | 2022-2025 | |
| Lilly USA, LLC | $372.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $212.36 | 2019-2021 | |
| Amgen INC. | $165.59 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $123.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $120.25 | 2019-2021 | |
| Glaxosmithkline, LLC. | $117.99 | 2022-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $110.64 | 2022-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $104.39 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $100.82 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.31 | 2020-2023 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $63.19 | 2019-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $62.97 | 2021 | |
| Eisai INC. | $59.71 | 2020-2021 | |
| Gilead Sciences, INC. | $57.83 | 2025 | |
| Abbott Laboratories | $53.43 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $52.86 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $43.55 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.57 | 2022 | |
| Dynavax Technologies Corporation | $31.10 | 2022-2025 | Heplisav-B |
| Clarus Therapeutics INC. | $29.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.47 | 2019-2021 | |
| Edwards Lifesciences Corporation | $20.17 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $16.87 | 2021 | |
| Lucid Diagnostics INC. | $16.77 | 2023 | |
| Allergan, INC. | $16.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.39 | 2025 | Zoryve |
| Grifols USA, LLC | $14.25 | 2021 | |
| Horizon Therapeutics Plc | $14.20 | 2019 | |
| Acerus Pharmaceuticals Corporation | $14.11 | 2021 | |
| Bausch Health US, LLC | $13.13 | 2020 | |
| Antares Pharma, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.